With this purchase you will earn points for subsequent purchases
Free shipping on orders over 39.00€
FACE - BODY
INDICATIONS
The 1st medical device, specific for the 3 types of eczema: atopic, chronic hand eczema, by contact.
PROPERTIES
A revolutionary care that: heals, repairs and reduces the appearance of breakouts. With 3 uses: alone in the areas of eczematous lesions, additionally and in the maintenance of the courses with dermocorticosteroids to accelerate their effectiveness.
instructions for use
Apply directly to inflamed eczema lesions. It is used alone or in combination with corticosteroids. 1 to 2 times a day. In case of combination with dermocorticosteroids: apply the dermocorticosteroid first, then Dexyane MeD. Precautions during use: Do not use if you are allergic to one of the ingredients. In case of allergic reaction consult a doctor. Avoid direct contact with eyes to avoid any irritation. In case of contact with eyes, rinse immediately with clean water. If eye irritation persists, consult a physician. Not to be used by pregnant or lactating women. Keep it away from children. Do not use in the femoral area of children wearing diapers, nor on the mucous membranes. The application should not exceed 30% of the body surface. Close the cap tightly after use.
PROVEN EFFICIENCY
IN COMBINATION: WITH DERMOCORTICOSTEROIDS Faster efficacy from 3rd day (1a) DEEPLY SENSITIVE ACTION -73% of pain from 8th day (2) in chronic hand eczema IN MAINTENANCE -83% of relapses at 15th day (1b) (1 case of relapse in the dexyane MeD group compared to the control group) (1) Intra-individual randomized controlled trial to evaluate the efficacy and tolerability of RV4421ABS0042 in combination with a moderately potent topical corticosteroid in adults with atopic dermatitis. Study RV4421A2013147,V1,04/03/16, PFDC a - Methodology: Comparative Clinical study in 54 adults aged 18 to 63 years with moderate to severe atopic dermatitis on hands or knees, 2 applications daily in combination with a topical dermocorticosteroid compared with dermocorticosteroid alone for 10 days, clinical grading after 3 days of application. Main endpoint: Reduction of L-SCORAD (Clinical Severity Scale from 0 to 18) at H3, including various signs such as pruritus. b - Methodology: Comparative Clinical study in 54 adults aged 18 to 63 years with moderate to severe atopic dermatitis on the hands or knees, 2 applications per day of dexyane MeD alone after the treatment phase of dexyane MeD in combination with a topical dermocorticosteroid. Primary endpoint: number of subjects with one relapse after 2 weeks of application. (2) Open-label study to evaluate the tolerability and efficacy of RV4421 ABS0042 applied for 3 weeks in adults with mild to moderate chronic hand dermatitis. Clinical study report RV4421A2013149, 29/02/2016 Methodology: Clinical study in 40 adults aged 20 - 66 with chronic hand eczema, 2 applications on 2 hands for 22 days. Main criterion: Local tolerance after 3 weeks of application. Secondary endpoint: MTLSS clinical severity scale score from 0 to 21. Pruritus (itching) and pain severity score (visual analog scale from 0 to 10), self-assessed after 8 days of application. Comparison with commonly used conditioner.
composition
WATER (AQUA), GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, BUTYLENE GLYCOL, POLYSORBATE 60, BUTYROSPERMUM PARKII (SHEA) BUTTER (BUTYROSPERMUM PARKII BUTTER), PROPYLENE GLYCOL, BEESWAX (CERA ALBA), GLYCERYL STEARATE, PEG-100 STEARATE, 10-HYDROXYDECENOIC ACID, CAPRYLYL GLYCOL, CETYL ALCOHOL, CITRIC ACID, DISODIUM EDTA, GLYCYRRHETINIC ACID, GUANIDINE CARBONATE, POLYACRYLATE-13, POLYSOBUTENE, POLYSORBATE 20, SCLEROTIUM GUM, SCLEROTIUM GUM
EAN: 3282770073355, 3282770148138
